Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07600749 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT07600749 is a Phase 1 study that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 120 participants.
The verdict
NCT07600749, a Phase 1 study, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.
Interventions
- DRUG MK-4884
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-06-18 |
| Est. Completion | 2029-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07600749
The ClinicalTrials.gov registry entry for NCT07600749 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MK-4884 is the first listed.
NCT07600749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07600749 about?
NCT07600749 is a clinical study titled "Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)". Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.
What is the current status of trial NCT07600749?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2026-06-18. Estimated completion is 2029-10-04.
What interventions are being tested in trial NCT07600749?
The interventions under investigation include: MK-4884 (DRUG).
Who is sponsoring clinical trial NCT07600749?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.